Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights
Retrieved on:
Tuesday, May 18, 2021
The increase of $2.2 million was primarily due to revenue recognition of additional milestone payment achieved pursuant to Legend Biotech\xe2\x80\x99s agreement with Janssen.
Key Points:
- The increase of $2.2 million was primarily due to revenue recognition of additional milestone payment achieved pursuant to Legend Biotech\xe2\x80\x99s agreement with Janssen.
- In the first quarter of 2021, this resulted in a larger amount of revenue recognized from the contract liabilities.
- In December 2017, Legend Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement to develop and commercialize cilta-cel.
- Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\n'